Why the study?
Does end-stage renal disease alter the pharmacokinetics of subcutaneous enoxaparin requiring dosage reduction?
Does end-stage renal disease alter the pharmacokinetics of subcutaneous enoxaparin requiring dosage reduction?
Standard dosing of enoxaparin appears to maintain therapeutic antifactor Xa levels in ESRD patients on hemodialysis, suggesting dosing adjustments may be unnecessary.
No takes yet. Share an insight, caveat, or question.
May support standard dosing without adjustment in ESRD on hemodialysis; hypothesis-generating and requires prospective validation before practice change.
Brophy et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: